You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address